Now that the majority of people living with HIV take combination antiretroviral therapy (ART), the
spectrum of causes of pyrexia of unknown origin (PUO) has changed compared with the pre-ART era.
In these guidelines, we focus on causes and evaluation of PUO among people living with HIV with
CD4 counts <3...
In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. CAB-LA is an injectable form of pre-exposure prophylaxis (PrEP) that has been shown to be highly effective at reducing...
As the HIV response moves to focusing on closing the remaining gaps in prevention, testing and treatment services, an evolution in the underlying routine data systems is needed to identify epidemiologic patterns and service gaps, and accelerate focused interventions.
These guidelines focus on the collec...
Cryptococcal disease is one of the most common opportunistic infections among people living with advanced HIV disease and is a major contributor to severe illness, morbidity, and mortality, particularly in sub-Saharan Africa.
These guidelines update the recommendations that were first released in 2018 ...
The leishmaniases are a group of diseases caused by Leishmania spp., which occur in cutaneous, mucocutaneous and visceral forms. They are neglected tropical diseases (NTDs), which disproportionately affect marginalized populations who have limited access to health care. HIV co-infected patients with Leis...
In 2019, 178 new HIV cases were diagnosed in Estonia (13.5 cases per 100,000 people). Among the new cases, the proportion of women was 37%. 53% of the new cases were discovered in Tallinn and 25% in Ida-Virumaa. Between 2010 and 2019, the number of new cases per year has decreased twice, but remains very...
These guidelines provide guidance on the diagnosis of HIV infection, the care of people living
with HIV and the use of antiretroviral (ARV) drugs for treating and preventing HIV infection.
They are structured along the continuum of HIV testing, prevention, treatment and care.
This edition updates the 201...
The primary audience for this guideline is national HIV programme managers, people living
with HIV, health-care providers and policy-makers in low- and middle-income countries. This
guideline update will be a useful resource for clinicians and should help to shape the priorities
of policy-makers in devel...
WHO promotes a public health approach to programming and delivering antiretroviral therapy (ART), which has enabled access to treatment and care for people living with HIV to be scaled up in resource-limited settings.
The 2016 WHO consolidated guidelines on the use of antiretroviral drugs for treating an...
Since 2007 the World Health Organization (WHO) and the Joint United Nations
Programme on HIV/AIDS (UNAIDS) have recommended voluntary medical male
circumcision (VMMC) as an important strategy for the prevention of heterosexually
acquired HIV in men in settings where the prevalence of heterosexually trans...
